BioMed Research International

BioMed Research International / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 713263 | 11 pages | https://doi.org/10.1155/2014/713263

The Wedelolactone Derivative Inhibits Estrogen Receptor-Mediated Breast, Endometrial, and Ovarian Cancer Cells Growth

Academic Editor: Hirotaka Iwase
Received25 Sep 2013
Accepted13 Feb 2014
Published13 Aug 2014

Abstract

Estrogen and estrogen receptor (ER)-mediated signaling pathways play important roles in the etiology and progression of human breast, endometrial, and ovarian cancers. Attenuating ER activities by natural products and their derivatives is a relatively practical strategy to control and reduce breast, endometrial, and ovarian cancer risk. Here, we found 3-butoxy-1,8,9-trihydroxy-6H-benzofuro[3,2-c]benzopyran-6-one (BTB), a new derivative of wedelolactone, could effectively inhibit the 17-estradiol (E2)-induced ER transactivation and suppress the growth of breast cancer as well as endometrial and ovarian cancer cells. Our results indicate that 2.5 μM BTB effectively suppresses ER-positive, but not ER-negative, breast, endometrial, and ovarian cancer cells. Furthermore, our data indicate that BTB can modulate ER transactivation and suppress the expression of E2-mediated ER target genes (Cyclin D1, E2F1, and TERT) in the ER-positive MCF-7, Ishikawa, and SKOV-3 cells. Importantly, this BTB mediated inhibition of ER activity is selective since BTB does not suppress the activities of other nuclear receptors, including glucocorticoid receptor and progesterone receptor, suggesting that BTB functions as a selective ER signaling inhibitor with the potential to treat breast, endometrial, and ovarian cancers.

1. Introduction

Breast, endometrial, and ovarian cancers are the three most common cancers among women in the United States and are the major causes of cancer related deaths in females. Breast, endometrial, and ovarian cancers are associated with excessive estrogen exposure. Based on hormonal responsiveness, the development of effective prevention strategies for breast, endometrial, and ovarian cancers is a paramount opportunity in the care of women at risk for those malignancies [1].

Estrogens are pleiotropic hormones that regulate the growth and differentiation of many diverse tissues. The action of estrogens is mediated through the estrogen receptor (ER), which belongs to the nuclear hormone receptor superfamily of ligand-activated transcription factors [2]. ER has two major subtypes, ERα and ERβ, each of which predominates in specific tissues and organs. Estrogens play crucial roles in many types of gynecological malignancies by modulating or substituting for ER-dependent activities [3]. It is now well established that estrogens play a fundamental role in promoting the growth and progression of ER-related cancer cells. This understanding and control of the ER pathways have led to the development of various endocrine therapies by blocking estrogen-mediated tumor growth and progression.

The proliferation of estrogen-dependent cancers is reduced by antiestrogen treatment in both dose- and time-dependent manners [4]. ICI 182,780 (ICI), a pure antiestrogen, is a steroidal molecule that can inhibit E2-mediated activity and induce apoptosis in estrogen-dependent cancer cells.

Traditional herb plants have a great importance due to their potential uses to treat diseases. Wedelia chinensis (Family: Asteraceae) has been used as a traditional Chinese medicine to treat septic shock, liver diseases, and viral infections [5]. This plant is a source of several secondary metabolites, such as flavonoids, phytosterols, and coumestans [6]. Coumestans represent an important class of natural oxygenated aromatic products, including wedelolactone. Wedelolactone (Figure 1(a)) is a naturally occurring furanocoumarin, which is an inhibitor of the IKK II [7], a kinase critical for the activation of NF-κB by mediating phosphorylation and degradation of IκBα. It also has many different bioactivities including antihepatotoxic, antihypertensive, antitumor, and antiphospholipase A2 properties, as well as being used as an antidote against snake venoms [811]. In addition to controlling NF-κB activity, wedelolactone is also known to possess estrogenic activity as it belongs to the coumestans family [12]. Recently, it was reported that wedelolactone inhibits growth of prostate and pituitary cancer cells [1315].

To enhance and improve the anticancer activity of wedelolactone, we modified the wedelolactone chemical structure and tested the bioactivities of ten new derivatives. Among those new derivatives, we found that 3-butoxy-1,8,9-trihydroxy-6H-benzofuro[3,2-c]-benzopyran-6-one (BTB) had antiestrogen activities. Its chemical structure is shown in Figure 1(a). This is the first study to discover and characterize the ability of BTB in regulating ER transactivation. We also analyzed BTB’s effects on mRNA expressions of ER target genes in different ER-positive cancer cells. It has been reported that estrogen/ER can activate the c-Myc and Cyclin D1 expression. Our data showed that the c-Myc and Cyclin D1 protein expression is regulated by estrogen/ERα, and the 17β-estradiol (E2)/ER-induced c-Myc/Cyclin D1 expression can be blocked by BTB treatment. We further investigated the the effects of BTB on cell growth in the estrogen-stimulatory environment using ER-positive versus ER-negative breast, endometrial, and ovarian cancer cell lines. Together, our data showed BTB could inhibit ER activity via decreasing the ER protein. BTB is a selective ER signaling inhibitor with the potential as therapeutic treatment for breast, endometrial, and ovarian cancers.

2. Materials and Methods

2.1. Chemicals and Reagents

At Shanghai Jiaotong University we modified wedelolactone and prepared ten new derivatives. We used the Sonogashira coupling reaction of 2-bromo-4,5-dibenzyloxyaniline with substituted phenylacetylene, a diazotization hydrolysis reaction, a ring closure, and deprotection reaction to obtain new derivatives. We screened their capability to inhibit ER and AR activities and found that the BTB had better antiestrogen activities. Commercial compounds and reagents including E2, ICI, dexamethasone (DEX), Mifepristone (RU-486), progesterone (P4), ethanol (EtOH), ethyl acetate (EtOAc), methanol, and chloroform (CHCl3) were purchased from Sigma (St. Louis, MO, USA). All other chemicals and solvents used in this study were of reagent or high performance liquid chromatography (HPLC) grade.

2.2. Plasmids

The plasmids used were pcDNA3.1-ERα, mouse mammary tumor virus (MMTV)-luciferase (Luc) reporter plasmid; plasmids pSG5-androgen receptor (pSG5-AR), pSG5 progesterone receptor (pSG5-PR), pSG5 glucocorticoid receptor (pSG5-GR), pWPI-Flag-ERβ, pGL3(ERE)3-Luc, and pRL-TK were constructed as described previously [1621].

2.3. Western Blot Analysis

50 μg of protein/lane was used for the analysis. The blots were probed with primary anti-ERα (Novocastra, 6F11), anti-c-Myc (cell signaling, #9402), anti-Cyclin D1 (#2922), anti-Stat3 (#9132), anti-pStat3 (#9145), anti-Akt (#9272), and anti-pAkt(S-473) (#9271) antibodies with dilutions of 1 : 500 to 1 : 1,000 and incubated at room temperature for 2 hrs. The secondary antibodies, horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgG, were used at room temperature for 1 hr. Immunoblot analysis was performed using enhanced chemiluminescence Western blotting detection reagents (Amersham Biosciences).

2.4. Cytotoxicity Assay In Vitro

Cytotoxicity assay was performed according to the protocol described in our previous publication [22]. To determine the IC50 value, 6.0 × 104 MDA-MB-231, Ishikawa, SKOV-3, HEC-1-A, and OVCA429 cells were plated in triplicate in 5% CS-FBS DMEM in 24-well culture plates. The cells were incubated with serial concentrations of BTB for 2 days and cell viability was determined by MTT assay. BTB + medium only (no cells) were included as a baseline reading to subtract the reading background. BTB treated cells were compared to DMSO treated cells. IC50 value was analyzed with the program CompuSyn (Developer). MCF-7 cells were seeded using RPMI-1640 with 5% CS-FBS medium. The IC50 of BTB in MCF-7 cells was tested with the same methods.

2.5. Statistics

Data are presented as the means ± SDs for the indicated number of separate experiments. The statistical significance of differences between two groups of data was analyzed by paired t-test and values <0.05 were considered significant.

Other methods including cell culture, luciferase assay, RNA extraction, reverse transcription, real-time PCR, and cell growth assay in vitro were described in the Supplementary Information (Doc. S1) available online at http://dx.doi.org/10.1155/2014/713263.

3. Results

3.1. BTB Selectively Inhibits the E2-Mediated ER Transactivation, Has a Less Inhibition Efficacy toward AR, and Fails to Inhibit the PR or the GR Mediated Transactivation

Nuclear receptors are ligand-dependent transcription factors that control a variety of essential physiologic and developmental processes as well as disease progression in humans [23]. For example, estrogen-ER signals were found to be crucial for breast, endometrial, and ovarian cancer development. As BTB belongs to the furanocoumarin family/group compound, which could possess the agonist or antagonist activity of ER, we first investigated the ability of BTB to regulate ER transactivation activity in the HEK 293 cells. The relative luciferase activity was determined within cells transiently transfected with ERs (ERα or ERβ) and an ERE-luciferase reporter construct, pGL3(ERE)3-Luc. ER’s transactivation activity was induced by E2 but blocked by the antiestrogen, ICI. Furthermore, our data showed that BTB was able to suppress E2-induced ER transactivation in a dose-dependent manner (Figures 1(b)-1(c)). In addition, we found 2.5 and 5.0 μM BTB treatments could effectively inhibit the ERα and ERβ transactivation but did not inhibit the AR transactivation. However, only when the concentration of BTB reached 10 μM did it start to show about 15–20% inhibition of the AR transactivation (Figure 1(d)).

To further confirm the ability of BTB to control ER transactivation activity, we used the ER-positive breast, endometrial, and ovarian cancer cells, MCF-7, Ishikawa, and SKOV-3, respectively, transfected with ERE-Luc. ER transactivation activities were induced by 10 nM E2 and could be blocked by ICI. Our data showed that BTB at the concentration of 2.5, 5.0, and 10 μM could effectively suppress E2-ER transactivation in the ER-positive MCF-7 breast cancer cells, Ishikawa endometrial cancer cells, and SKOV-3 ovarian cancer cells (Figures 1(e)1(g)).

We further evaluated the effect of BTB on P4-induced PR transcriptional activity in Ishikawa cells transfected with PR and a MMTV-luciferase reporter. PR transactivation activity was induced by 10 nM P4 and blocked by 10 μM RU486. However, BTB had no inhibitory effect on P4-mediated PR transactivation (Figure 1(h)). In comparison, we tested whether BTB can inhibit the GR mediated transactivation, and as shown in Figure 1(i), the antagonist RU486 can, but BTB cannot, inhibit the Dex-GR activities. Together, 2.5 or 5 μM BTB treatment selectively inhibits ER activity but not AR, PR, or GR transactivation. 10 μM BTB starts to show a marginal 15%–20% inhibitory effect on AR and still has no effect on PR and GR transactivations.

3.2. BTB Inhibits the E2-Induced Growth in ER-Positive, but Not in ER-Negative, Breast, Endometrial, and Ovarian Cancer Cells

As BTB could selectively inhibit the ER-mediated transactivation, we then investigated the effects of BTB on the inhibition of E2-induced cell proliferation in ER-positive MCF7, Ishikawa, and SKOV-3 cancer cells and compared this with the ER-negative MDA-MB-231, HEC-1-A, and OVCA429 cancer cells. BTB reduced E2-induced cell growth in MCF-7, Ishikawa, and SKOV-3 cells by 50%, 55%, and 62%, respectively (Figures 2(a)2(c)). As shown in Figure 1, 2.5 μM BTB treatment could not completely block E2-induced ER transactivation on ERE-luciferase; we did not expect to see 100% completion of E2 stimulated growth. On the other hand, BTB failed to inhibit the growth of those three ER-negative cancer cell lines in the presence or in the absence of E2 (Figures 2(d) and 2(f)).

The half maximal inhibitory concentration (IC50) can be determined by constructing a dose-response curve and examining the effect of different concentrations of antagonists on reversing the agonist activity [18, 24]. The IC50 concentrations for BTB on the breast, endometrial, and ovarian cancer cell lines were evaluated by half-inhibition of cell growth after 48 hr of BTB treatments in the presence or absence of 10 nM E2. In the presence of 10 nM E2, the IC50 concentrations for BTB in MCF-7, Ishikawa, SKOV-3, MDA-MB-231, HEC-1-A, and OVCA429 were μM, μM, μM, μM, , and μM, respectively (Figure 3). In the absence of E2, the IC50 concentrations for BTB in those cell lines were μM, μM, μM, μM, μM, and μM, respectively. As shown in Figure 1, 2.5 uM BTB treatment could not completely block E2-induced ER transactivation on ERE-luciferase. Therefore, we did not expect to see that BTB could 100% inhibit E2 stimulated growth. Together, we used multiple assays and reproducibly found that BTB could effectively inhibit the ER-positive MCF-7, Ishikawa, and SKOV-3 cell growth. Therefore, we determined the mechanisms by which BTB controls ER activity and cancer cell growth in ER-positive MCF-7, Ishikawa, and SKOV-3 cells.

3.3. BTB Inhibits the E2-Induced ER Target Gene Expression in MCF-7, Ishikawa, and SKOV-3 Cells

As shown in Figure 1, we observed that 2.5 μM BTB could effectively inhibit ER/ERE-Luc activity. Although our results show BTB can inhibit both ERα and ERβ, ERα seems to play a more dominant role in those 3 female cancers. Earlier reports showed that ERα, but not ERβ, is overexpressed in breast, endometrial, and ovarian cancers [2527].

Therefore, we focused on the ERα in the following studies. To further illustrate the ability of BTB to regulate the ER downstream pathway, we assayed ER target genes in the ER-positive cells, MCF-7, Ishikawa, and SKOV-3 treated with 25 μM BTB treatment. Our data show that the mRNA expression of ER target genes, Cyclin D1, E2F1, and TERT [2830], was induced by 10 nM E2, and the treatment with 2.5 μM BTB could effectively suppress the E2-induced ER target genes expression in MCF-7, Ishikawa, and SKOV-3 cells (Figure 4).

3.4. BTB Inhibits the E2-Induced ERα, c-Myc, and Cyclin D1 Protein Levels in MCF-7, Ishikawa, and SKOV-3 Cells

Our data showed that BTB inhibited the ER mediated activity and target gene expression, yet the mechanism remains unclear. At the same time, using RT-PCR, we observed that the treatment with BTB did not change the ERα mRNA levels in MCF-7, Ishikawa, and SKOV-3 cells (Figures 5(a)5(c)). Our data showed that BTB treatment significantly inhibited the protein levels of ERα and E2-induced target genes (Figures 5(d)5(f)).

We also determined the effect of BTB on E2-induced protein levels of c-Myc and Cyclin D1 in MCF-7, Ishikawa, and SKOV-3 cells. Our data showed that the protein levels of c-Myc and Cyclin D1 were induced by E2, and BTB significantly inhibited the c-Myc and Cyclin D1 protein expressions (Figures 5(d)5(f)).

3.5. BTB Fails to Affect the Expression Levels and the Phosphorylation Status of Akt and STAT3 in ER-Positive Cancer Cells

In addition to E2/ERα, it has been documented that Akt and STAT3 are important cancer survival pathways in those cancer cells [31, 32]. Our data showed that BTB could effectively inhibit the growth of MCF-7, Ishikawa, and SKOV-3. Other than ERα, it is of great interest to test whether BTB can affect the activity of Akt or STAT3. Cancer cells were seeded in phenol red free DMEM media with 10% CS-FBS for 48 hrs and then treated with BTB or EtOH in the presence or absence of 10 nM E2 for 24 hrs. The cells were harvested and lysates were subjected to electrophoresis and Western blotting analyses.

Our data showed that the BTB mediated growth suppression did not affect the expression level of the phosphorylation of Akt (s473) and STAT3 in ER-positive cancer cells (Figures 6(a)6(c)) and demonstrated the specificity of BTB effects on ER signaling pathway to modulate growth and survival of 3 major types of female cancers.

4. Discussion

Hormonal therapy targeting ER signaling is one of the most effective treatments for steroid hormone related cancer. In the current study, we showed that the new derivative compound BTB, which was modified from wedelolactone, has the potential in breast cancer and gynecological cancer therapy by inhibition of ER signaling.

The chemical structure of wedelolactone designates it as part of the coumestans family, which is known to possess estrogenic activity [12]. Recently, it was shown that wedelolactone is able to suppress AR activity and inhibit cell growth in AR positive prostate cancer cells [1315]. Interestingly, the new derivative BTB at 2.5 or 5.0 μM concentrations can efficiently inhibit both ERα and ERβ transcriptional activity but only inhibit AR activity at a higher dose. Meanwhile, other steroid receptor signaling pathways, including PR and GR, are not affected even at the higher doses, indicating that BTB selectively inhibits ER signaling. In addition, 2.5 or 5.0 μM of BTB treatments for 24 or 48 hrs could not induce apoptotic signals in those 3 cancer cell lines (data not shown). It was reported that several signaling pathways, like phosphorylation of Akt or STAT3, may contribute to the cancer cells growth and progression [3337]. However, the BTB mediated growth suppression did not affect those signal pathways and was only effective in ER-positive cancer cells, again demonstrating the specificity of BTB effect on the ER signaling pathway.

The estrogen antagonists can inhibit the transcriptional activity of ER, but some of the estrogen-dependent cancer cells can escape this competitive inhibition and activate the ER signaling pathway by growth factors or coactivators, suggesting that the direct targeting on ER protein could be an important therapeutic strategy in those advanced cancer cells [38, 39]. Our data showed that BTB could decrease the E2-induced ERα protein level but not the mRNA level, indicating that the inhibition effect may function through translational repression or protein degradation. It would be interesting to study how BTB reduces ER protein level and what is the potential implication in cancer therapy.

In the estrogen-related cancer cells, many of the ERα downstream target genes were reported to play important roles in cell growth and survival, which may be linked to tumor progression. In those ER-related cancer cells, E2-activated ERα modulates the expression of key cell cycle regulatory genes, including Cyclin D1 [30, 40] and the transcription factor E2F1 [28]. These factors play important roles in cell cycle progression, directing the phosphorylation and inactivation of the retinoblastoma protein and mediating the expression of genes involved in DNA replication and S phase entry [41].

Human telomerase reverse transcriptase (hTERT) is a catalytic subunit of telomerase. Some studies have found that hTERT is expressed in most malignant tumors, but not in normal somatic cells, and that its expression is closely associated with telomerase activity [29]. E2 activates hTERT transcription through the direct interaction of ligand-activated ER with the ERE sequence located at 72677 in the hTERT 5′ regulatory region in endometrial cancer cells [42], implying the existence of hormone-dependent control mechanisms of telomerase activity. The overexpression or amplification of c-Myc was observed in many types of cancers [43]. It was also proven that c-Myc could play important roles in cancer cell growth, apoptosis, metabolism, and cell differentiation [44]. Since it was demonstrated that E2 treatment could enhance the c-Myc expression in ovarian cancer cells [45], inhibition of c-Myc expression through blocking estrogen signaling may also contribute to the suppression of cancer progression.

In brief, the current data indicated that our new wedelolactone derivative BTB can specifically inhibit the ER signaling and block the E2 stimulated cell proliferation in the estrogen-related cancers. Decreased ERα protein was observed, and the ERα downstream target protein was also reduced in BTB treated cells. The potential clinical application of BTB use in the treatment of breast cancer and possibly in other gynecological cancers will be interesting for the further study.

Abbreviations

AR:Androgen receptor
BTB:3-Butoxy-1,8,9-trihydroxy-6H-benzofuro[3,2-c] benzopyran-6-one
DEX:Dexamethasone
ER:Estrogen receptor
ERE:Estrogen-responsive element
E2:17β-Estradiol
ICI:ICI 182,780
GR:Glucocorticoid receptor
Luc:Luciferase
P4:Progesterone
PR:Progesterone receptor
hTERT:Human telomerase reverse transcriptase.

Conflict of Interests

The authors declare that there is no conflict of interests that could be perceived as prejudicing the impartiality of the research reported.

Authors’ Contribution

Defeng Xu and Tzu-Hua Lin contributed equally to this work.

Acknowledgments

The authors thank Karen Wolf for assistance in paper preparation. This work was supported by the George Whipple Professor Endowment.

Supplementary Materials

The supplementary document includes detailed methods for I. Cell Culture, II. In Vitro Cell Growth Assay, III. Luciferase Assay, and IV. RNA Extraction, Reverse transcription, and Real-time PCR.

  1. Supplementary Materials

References

  1. L. W. Rice, “Hormone prevention strategies for breast, endometrial and ovarian cancers,” Gynecologic Oncology, vol. 118, no. 2, pp. 202–207, 2010. View at: Publisher Site | Google Scholar
  2. Y. M. Shah and B. G. Rowan, “The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor α promoter interaction and elevated steroid receptor coactivator 1 activity,” Molecular Endocrinology, vol. 19, no. 3, pp. 732–748, 2005. View at: Publisher Site | Google Scholar
  3. C. K. Osborne, H. Zhao, and S. A. W. Fuqua, “Selective estrogen receptor modulators: structure, function, and clinical use,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3172–3186, 2000. View at: Google Scholar
  4. G. Freiss, C. Puech, and F. Vignon, “Extinction of insulin-like growth factor-i mitogenic signaling by antiestrogen-stimulated fas-associated protein tyrosine phosphatase-1 in human breast cancer cells,” Molecular Endocrinology, vol. 12, no. 4, pp. 568–579, 1998. View at: Google Scholar
  5. M. A. H. Mollik, M. S. H. Hossan, A. K. Paul, M. Taufiq-Ur-Rahman, R. Jahan, and M. Rahmatullah, “A comparative analysis of medicinal plants used by folk medicinal healers in three districts of Bangladesh and inquiry as to mode of selection of medicinal plants,” Ethnobotany Research and Applications, vol. 8, pp. 195–218, 2010. View at: Google Scholar
  6. A. M. S. Pereira, B. W. Bertoni, A. Menezes Jr., P. S. Pereira, and S. C. Franca, “Soil pH and production of biomass and wedelolactone in field grown Eclipta alba,” Journal of Herbs, Spices and Medicinal Plants, vol. 6, no. 1, pp. 43–48, 1998. View at: Publisher Site | Google Scholar
  7. M. Kobori, Z. Yang, D. Gong et al., “Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex,” Cell Death and Differentiation, vol. 11, no. 1, pp. 123–130, 2004. View at: Publisher Site | Google Scholar
  8. A. K. Saxena, B. Singh, and K. K. Anand, “Hepatoprotective effects of Eclipta alba on subcellular levels in rats,” Journal of Ethnopharmacology, vol. 40, no. 3, pp. 155–161, 1993. View at: Publisher Site | Google Scholar
  9. A. M. Soares, F. K. Ticli, S. Marcussi et al., “Medicinal plants with inhibitory properties against snake venoms,” Current Medicinal Chemistry, vol. 12, no. 22, pp. 2625–2641, 2005. View at: Publisher Site | Google Scholar
  10. H. Wagner, B. Geyer, and Y. Kiso, “Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea,” Planta Medica, vol. 5, pp. 370–374, 1986. View at: Google Scholar
  11. L. C. Diogo, R. S. Fernandes, S. Marcussi et al., “Inhibition of snake venoms and phospholipases A2 by Extracts from native and genetically modified Eclipta alba: isolation of active coumestans,” Basic and Clinical Pharmacology and Toxicology, vol. 104, no. 4, pp. 293–299, 2009. View at: Publisher Site | Google Scholar
  12. N. Uddin, A. Rahman, N. U. Ahmed et al., “Antioxidant, cytotoxic and antimicrobial properties of Eclipta albaethanol extract,” International Journal of Biological and Medical Research, vol. 1, no. 4, pp. 341–334, 2010. View at: Google Scholar
  13. F. M. Lin, L. R. Chen, E. H. Lin et al., “Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells,” Carcinogenesis, vol. 28, no. 12, pp. 2521–2529, 2007. View at: Publisher Site | Google Scholar
  14. C. H. Tsai, F. M. Lin, Y. C. Yang et al., “Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice,” Clinical Cancer Research, vol. 15, no. 17, pp. 5435–5444, 2009. View at: Publisher Site | Google Scholar
  15. J. R. Vender, M. D. Laird, and K. M. Dhandapani, “Inhibition of nfκb reduces cellular viability in gh3 pituitary adenoma cells,” Neurosurgery, vol. 62, no. 5, pp. 1122–1128, 2008. View at: Publisher Site | Google Scholar
  16. M. Chen, J. Ni, H. Chang, C. Lin, M. Muyan, and S. Yeh, “CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells,” Carcinogenesis, vol. 30, no. 5, pp. 841–850, 2009. View at: Publisher Site | Google Scholar
  17. M. Chen, J. Ni, Y. Zhang, M. Muyan, and S. Yeh, “ERAP75 functions as a coactivator to enhance estrogen receptor α transactivation in prostate stromal cells,” Prostate, vol. 68, no. 12, pp. 1273–1282, 2008. View at: Publisher Site | Google Scholar
  18. D. Xu, T. Lin, S. Li et al., “Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells,” Cancer Letters, vol. 316, no. 1, pp. 11–22, 2012. View at: Publisher Site | Google Scholar
  19. D. Xu, T. Lin, C. Zhang et al., “The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells,” Prostate, vol. 72, no. 7, pp. 803–816, 2012. View at: Publisher Site | Google Scholar
  20. S. Yeh, Y. Hu, M. Rahman et al., “Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11256–11261, 2000. View at: Google Scholar
  21. S. Yeh, H. K. Lin, H. Y. Kang, T. H. Thin, M. Lin, and C. Chang, “From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5458–5463, 1999. View at: Publisher Site | Google Scholar
  22. J. Ni, S. Pang, and S. Yeh, “Differential retention of α-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells,” Prostate, vol. 67, no. 5, pp. 463–471, 2007. View at: Publisher Site | Google Scholar
  23. S. Tenbaum and A. Baniahmad, “Nuclear receptors: structure, function and involvement in disease,” International Journal of Biochemistry and Cell Biology, vol. 29, no. 12, pp. 1325–1341, 1997. View at: Publisher Site | Google Scholar
  24. N. Harada, K. Inoue, R. Yamaji, Y. Nakano, and H. Inui, “Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells,” Cancer Science, vol. 103, no. 6, pp. 1022–1027, 2012. View at: Publisher Site | Google Scholar
  25. J. H. Choi, K. T. Lee, and P. C. K. Leung, “Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth,” Carcinogenesis, vol. 32, no. 4, pp. 589–596, 2011. View at: Publisher Site | Google Scholar
  26. Y. Miyoshi, K. Murase, M. Saito, M. Imamura, and K. Oh, “Mechanisms of estrogen receptor-α upregulation in breast cancers,” Medical Molecular Morphology, vol. 43, no. 4, pp. 193–196, 2010. View at: Publisher Site | Google Scholar
  27. J. S. Tong, Q. H. Zhang, Z. B. Wang et al., “ER-α36, a novel variant of ER-α, mediates estrogen stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway,” PLoS ONE, vol. 5, no. 11, Article ID e15408, 2010. View at: Publisher Site | Google Scholar
  28. M. C. Louie, A. McClellan, C. Siewit, and L. Kawabata, “Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance,” Molecular Cancer Research, vol. 8, no. 3, pp. 343–352, 2010. View at: Publisher Site | Google Scholar
  29. S. Misiti, S. Nanni, G. Fontemaggi et al., “Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells,” Molecular and Cellular Biology, vol. 20, no. 11, pp. 3764–3771, 2000. View at: Publisher Site | Google Scholar
  30. C. Yang, L. Chen, C. Li, M. C. Lynch, C. Brisken, and E. V. Schmidt, “Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression,” Molecular and Cellular Biology, vol. 30, no. 12, pp. 3111–3125, 2010. View at: Publisher Site | Google Scholar
  31. N. A. Binai, A. Damert, G. Carra et al., “Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells,” International Journal of Cancer, vol. 127, no. 1, pp. 55–66, 2010. View at: Publisher Site | Google Scholar
  32. S. Bose, S. Chandran, J. M. Mirocha, and N. Bose, “The Akt pathway in human breast cancer: a tissue-array-based analysis,” Modern Pathology, vol. 19, no. 2, pp. 238–245, 2006. View at: Publisher Site | Google Scholar
  33. S. Haftchenary, M. Avadisian, and P. T. Gunning, “Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report,” Anti-Cancer Drugs, vol. 22, no. 2, pp. 115–127, 2011. View at: Publisher Site | Google Scholar
  34. D. Lane, N. Goncharenko-Khaider, C. Rancourt, and A. Piché, “Ovarian cancer ascites protects from TRAIL-induced cell death through αvΒ5 integrin-mediated focal adhesion kinase and Akt activation,” Oncogene, vol. 29, no. 24, pp. 3519–3531, 2010. View at: Publisher Site | Google Scholar
  35. K. Stemke-Hale, A. M. Gonzalez-Angulo, A. Lluch et al., “An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer,” Cancer Research, vol. 68, no. 15, pp. 6084–6091, 2008. View at: Publisher Site | Google Scholar
  36. J. Z. Tang, X. J. Kong, A. Banerjee et al., “STAT3α is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone,” Endocrinology, vol. 151, no. 9, pp. 4133–4145, 2010. View at: Publisher Site | Google Scholar
  37. J. J. Wallin, J. Guan, W. W. Prior et al., “Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer,” Science Translational Medicine, vol. 2, no. 48, Article ID 48ra66, 2010. View at: Publisher Site | Google Scholar
  38. S. H. Park, L. W. Cheung, A. S. Wong, and P. C. Leung, “Estrogen regulates snail and slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor α,” Molecular Endocrinology, vol. 22, no. 9, pp. 2085–2098, 2008. View at: Publisher Site | Google Scholar
  39. E. Weiderpass, I. Persson, H. Melhus, S. Wedrén, A. Kindmark, and J. A. Baron, “Estrogen receptor α gene polymorphisms and endometrial cancer risk,” Carcinogenesis, vol. 21, no. 4, pp. 623–627, 2000. View at: Google Scholar
  40. L. Tian, Z. Wu, Y. Zhao et al., “Differential induction of LRP16 by liganded and unliganded estrogen receptor α in SKOV3 ovarian carcinoma cells,” Journal of Endocrinology, vol. 202, no. 1, pp. 167–177, 2009. View at: Publisher Site | Google Scholar
  41. C. Giacinti and A. Giordano, “RB and cell cycle progression,” Oncogene, vol. 25, no. 38, pp. 5220–5227, 2006. View at: Publisher Site | Google Scholar
  42. Z. Wang, S. Kyo, Y. Maida et al., “Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells,” Oncogene, vol. 21, no. 22, pp. 3517–3524, 2002. View at: Publisher Site | Google Scholar
  43. M. Vita and M. Henriksson, “The Myc oncoprotein as a therapeutic target for human cancer,” Seminars in Cancer Biology, vol. 16, no. 4, pp. 318–330, 2006. View at: Publisher Site | Google Scholar
  44. S. Bircan, A. Ensari, S. Ozturk, N. Erdogan, I. Dundar, and F. Ortac, “Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium,” Pathology and Oncology Research, vol. 11, no. 1, pp. 32–39, 2005. View at: Google Scholar
  45. C. H. Chien, F. F. Wang, and T. C. Hamilton, “Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells,” Molecular and Cellular Endocrinology, vol. 99, no. 1, pp. 11–19, 1994. View at: Publisher Site | Google Scholar

Copyright © 2014 Defeng Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1500 Views | 590 Downloads | 8 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.